SynthesisInternational journal of colorectal disease2026
Risk factors for rebleeding in acute lower gastrointestinal bleeding: a systematic review and meta-analysis.
Synthesis in International journal of colorectal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the potential risk factors for rebleeding following acute lower gastrointestinal bleeding (ALGIB).
methodsA comprehensive literature review was performed utilizing the PubMed, Embase, Web of Science, and Cochrane Library databases, encompassing articles published up to May 10, 2024. Two researchers independently performed literature screening, data extraction, and risk of bias assessment to ensure methodological rigor and minimize potential biases. The meta-analysis was performed using R (version 4.3.2) and Stata 17.0 software.
resultsA total of 2799 studies were retrieved, of which 29 were ultimately included in the analysis, comprising 23 case-control studies and 6 cohort studies, involving 14,069 patients with ALGIB, of whom 1930 experienced rebleeding. The pooled results of multivariable meta-analysis indicated that age ≥ 70 years, blood transfusion requirements, shock at presentation, hypertension, comorbid chronic kidney disease (CKD), hyperlipidemia, NSAIDs use, active bleeding on colonoscopy, colonic diverticular bleeding, and non-aspirin antiplatelet treatment are risk factors for rebleeding after ALGIB. In addition, the results of univariable analysis also showed that steroids, aspirin, and anticoagulant drug use are associated factors for rebleeding.
conclusionBased on available evidence, several factors, including age ≥ 70 years, blood transfusion requirements, shock at presentation, hypertension, CKD, hyperlipidemia, NSAIDs use, active bleeding on colonoscopy, colonic diverticular bleeding, and non-aspirin antiplatelet treatment, may be associated with an increased risk of rebleeding after ALGIB. Early identification of these risk factors and implementation of individualized interventions may help improve patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.